Empowering specificity of AML immunotherapies by HSC engineering |
Boston Children’s Hospital / Pietro Genovese |
Catalyst Grants |
2023 |
Massachusetts |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Targeting the biological underpinnings of pulmonary metastasis in osteosarcoma |
Dana-Farber Cancer Institute / Rani George, MD/PhD |
Crazy 8 Awards |
2022 |
Massachusetts |
GENOME ORIGAMI: Refolding Aberrant Chromosome 3D Structure for Treating NUT Carcinoma |
Baylor College of Medicine / Kyle Eagen, PhD |
R Accelerated Award Grants |
2022 |
Texas |
Targeting Kinase Inhibitor Induced DNA-Damage Response in Ph-Like ALL |
Temple University / Christian Hurtz, PhD |
'A' Award Grants |
2022 |
Pennsylvania |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma |
Dana-Farber Cancer Institute / Rani George, MD, PhD |
Innovation Grants |
2022 |
Massachusetts |
Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy |
University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD |
Innovation Grants |
2022 |
Wisconsin |
Blocking the Evil Messenger in MYCN-driven High-risk Neuroblastoma |
Boston University / Hui Feng, Md, PhD |
Innovation Grants |
2022 |
Massachusetts |